Leerink Partners analyst Thomas Smith has maintained their bullish stance on MDGL stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Smith’s rating is based on several key factors that highlight the potential of Madrigal Pharmaceuticals. Firstly, the commercial success of Rezdiffra, the first FDA-approved therapy for MASH, is a significant driver, with expected revenues surpassing consensus estimates. This optimism is supported by the recent Notice of Allowance for a method of use patent, which could extend Rezdiffra’s exclusivity until 2044, providing a competitive edge.
Additionally, the company’s strategic acquisition of the oral GLP-1, SYH2086, and the anticipated EU approval for Rezdiffra further bolster its growth prospects. The potential FDA approval and launch of semaglutide by NVO in the latter half of 2025 also play a role in shaping the market landscape. Overall, Thomas Smith is encouraged by Madrigal’s business development and regulatory achievements, which are expected to enhance the strategic value of Rezdiffra in the future.
According to TipRanks, Smith is a top 100 analyst with an average return of 44.3% and a 53.77% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Disc Medicine, and Sagimet Biosciences, Inc. Class A.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $500.00 price target.